BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Net Assets

Latest as of March 2026: Rs2.49 Billion INR ≈ $26.94 Million USD

Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has net assets worth Rs2.49 Billion INR (≈ $26.94 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.37 Billion ≈ $36.45 Million USD) and total liabilities (Rs879.53 Million ≈ $9.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BALAXI PHARMACEUTICALS LIMITED (BALAXI) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs2.49 Billion
% of Total Assets	73.9%
Annual Growth Rate	56.26%
5-Year Change	120.1%
10-Year Change	10457.81%
Growth Volatility	1956.7

BALAXI PHARMACEUTICALS LIMITED - Net Assets Trend (2013–2026)

This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BALAXI market cap.

Annual Net Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2026)

The table below shows the annual net assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2026. Also explore BALAXI PHARMACEUTICALS LIMITED net asset momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-03-31	Rs2.49 Billion ≈ $26.94 Million	+7.48%
2025-03-31	Rs2.32 Billion ≈ $25.06 Million	+15.08%
2024-03-31	Rs2.01 Billion ≈ $21.78 Million	+10.11%
2023-03-31	Rs1.83 Billion ≈ $19.78 Million	+61.61%
2022-03-31	Rs1.13 Billion ≈ $12.24 Million	+74.15%
2021-03-31	Rs649.80 Million ≈ $7.03 Million	+134.20%
2020-03-31	Rs277.46 Million ≈ $3.00 Million	+688.12%
2019-03-31	Rs35.21 Million ≈ $380.73K	+126.46%
2018-03-31	Rs15.55 Million ≈ $168.13K	-34.10%
2017-03-31	Rs23.59 Million ≈ $255.13K	+7392.46%
2016-03-31	Rs314.87K ≈ $3.41K	-2.35%
2015-03-31	Rs322.45K ≈ $3.49K	-95.86%
2014-03-31	Rs7.80 Million ≈ $84.33K	+3.67%
2013-03-31	Rs7.52 Million ≈ $81.34K	--

Equity Component Analysis

This analysis shows how different components contribute to BALAXI PHARMACEUTICALS LIMITED's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs110.42 Million	4.43%
Other Components	Rs2.38 Billion	95.57%
Total Equity	Rs2.49 Billion	100.00%

BALAXI PHARMACEUTICALS LIMITED Competitors by Market Cap

The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their market capitalization.

Company	Market Cap
Serstech AB ST:SERT	$14.07 Million
INOVIQ LTD. F:EGQ0	$14.07 Million
ERSU Meyve ve Gida Sanayi AS IS:ERSU	$14.08 Million
Artroniq Berhad KLSE:0038	$14.08 Million
MYMBN Berhad KLSE:0280	$14.05 Million
PIMS Inc. KQ:347770	$14.05 Million
MMS Ventures Bhd KLSE:0113	$14.05 Million
Akritas S.A AT:AKRIT	$14.04 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BALAXI PHARMACEUTICALS LIMITED's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 2,317,363,000 to 2,490,763,000, a change of 173,400,000 (7.5%).
Net income of 14,169,000 contributed positively to equity growth.
Other comprehensive income decreased equity by 6,437,000.
Other factors increased equity by 165,668,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs14.17 Million	+0.57%
Other Comprehensive Income	Rs-6.44 Million	-0.26%
Other Changes	Rs165.67 Million	+6.65%
Total Change	Rs-	7.48%

Book Value vs Market Value Analysis

This analysis compares BALAXI PHARMACEUTICALS LIMITED's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.52x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 164.93x to 0.52x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-03-31	Rs0.14	Rs23.55	x
2014-03-31	Rs0.15	Rs23.55	x
2015-03-31	Rs0.01	Rs23.55	x
2016-03-31	Rs0.01	Rs23.55	x
2017-03-31	Rs7.76	Rs23.55	x
2018-03-31	Rs0.30	Rs23.55	x
2019-03-31	Rs0.67	Rs23.55	x
2020-03-31	Rs5.27	Rs23.55	x
2021-03-31	Rs12.34	Rs23.55	x
2022-03-31	Rs21.49	Rs23.55	x
2023-03-31	Rs34.72	Rs23.55	x
2024-03-31	Rs38.23	Rs23.55	x
2025-03-31	Rs41.92	Rs23.55	x
2026-03-31	Rs45.71	Rs23.55	x

Capital Efficiency Dashboard

This dashboard shows how efficiently BALAXI PHARMACEUTICALS LIMITED utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.57%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.52%
• Asset Turnover: 0.81x
• Equity Multiplier: 1.35x
Recent ROE (0.57%) is below the historical average (15.21%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	5.88%	51.33%	0.07x	1.65x	Rs-309.88K
2014	14.05%	56.78%	0.16x	1.54x	Rs315.65K
2015	317.43%	82.71%	3.36x	1.14x	Rs991.30K
2016	-255.26%	-169.17%	1.33x	1.13x	Rs-835.21K
2017	-33.47%	0.00%	-0.24x	1.09x	Rs-10.25 Million
2018	-49.65%	0.00%	0.00x	1.08x	Rs-9.27 Million
2019	55.84%	14.46%	2.23x	1.73x	Rs16.14 Million
2020	22.00%	13.38%	1.27x	1.30x	Rs33.29 Million
2021	58.69%	16.49%	2.32x	1.53x	Rs316.39 Million
2022	42.11%	17.06%	1.58x	1.56x	Rs363.41 Million
2023	25.13%	13.66%	1.40x	1.31x	Rs276.75 Million
2024	-1.19%	-0.99%	0.93x	1.28x	Rs-225.23 Million
2025	10.82%	8.68%	0.93x	1.34x	Rs18.97 Million
2026	0.57%	0.52%	0.81x	1.35x	Rs-234.91 Million

Industry Comparison

This section compares BALAXI PHARMACEUTICALS LIMITED's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $55,732,551,119
Average return on equity (ROE) among peers: 12.78%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
BALAXI PHARMACEUTICALS LIMITED (BALAXI)	Rs2.49 Billion	5.88%	0.35x	$14.06 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$31.32 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$426.21 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$804.25 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$6.27 Billion
Ajanta Pharma Limited (AJANTPHARM)	$29.96 Billion	21.83%	0.26x	$4.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.30 Billion
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$7.07 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.29 Billion	15.52%	0.29x	$154.33 Million
Alembic Pharmaceuticals Limited (APLLTD)	$52.38 Billion	9.95%	0.36x	$1.80 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$326.47 Billion	10.68%	0.52x	$10.79 Billion

About BALAXI PHARMACEUTICALS LIMITED

NSE:BALAXI India Drug Manufacturers - Specialty & Generic

Market Cap

$14.06 Million

Rs1.30 Billion INR

Market Cap Rank

#26264 Global

#1447 in India

Share Price

Rs23.55

Change (1 day)

+2.21%

52-Week Range

Rs15.67 - Rs47.01

All Time High

Rs207.74